{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 95,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a clear 'problem-solution' structure typical of activist investor decks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/6",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.67,
        "x": 0.165,
        "y": 0.79
      },
      "kind": "callout",
      "text": "If elected the candidates will drive accountability, put the Company’s clinical programs back on track, and restore value for all shareholders.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e93f67fe-7e99-4dc8-ab20-524c8a6e8736",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.77,
        "x": 0.115,
        "y": 0.275
      },
      "kind": "callout",
      "text": "Under the oversight of the MindMed board of directors (the “Board”) since CEO Robert Barrow was appointed:",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd57a6ff-46b2-4c3f-9960-a3dd9615e44f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.884,
        "x": 0.058,
        "y": 0.348
      },
      "kind": "list",
      "text": "MindMed has embarked on a flawed and value destructive clinical strategy; Shareholders have experienced a dramatic under-performance; Executive compensation has soared; MindMed has repeatedly rebuffed our entreaties to help.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86362708-ce97-4b73-83e9-fcbfe76c61b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.884,
        "x": 0.058,
        "y": 0.202
      },
      "kind": "paragraph",
      "text": "MindMed is an early-stage biopharmaceutical company developing psychedelic medicines with its lead drug candidate being LSD (MM-120).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "094885cb-2799-4cb6-addf-3971a9ae90ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.778,
        "x": 0.111,
        "y": 0.594
      },
      "kind": "paragraph",
      "text": "FCM MM Holdings, LLC (“FCM”, or “We”), beneficial owner of 3.5% of MindMed shares, is nominating four new highly experienced, qualified director candidates to transform MindMed into a leading psychedelic company.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f3ad2ab-6f6a-46dc-967b-dc6ee37aaaf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.18,
        "x": 0.02,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Company SEC filings. See [1]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9718892-7bb3-48c7-ac91-f86099359723",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.33,
        "x": 0.047,
        "y": 0.047
      },
      "kind": "title",
      "text": "Introduction",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d09ba73-0d31-4b88-90a7-faddb4a5fcfb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "df8dd34d-e84f-4c92-8a10-afc702fe500f",
      "evidence": "The slide explicitly frames the current board and CEO as the cause of value destruction.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}